Genialis™ krasID

First-in-class patient classifier predicts response and stratifies clinical benefit of KRAS inhibition

Genialis krasID is designed to predict and monitor drug response from the simplest preclinical models to real world patient cohorts.

Schedule a free consultation with our experts to explore how it can benefit your drug development!

Off-the-shelf or optimized to your compound, Genialis krasID is ready to support your translational and clinical development.

Genialis krasID was developed using the Genialis™ Supermodel and ResponderID™ methodology.

RNA-Seq data icon

1. Your RNA data

Your data can be used to tune Genialis krasID to meet your clinical development needs.

Genialis Supermodel icon

2. Genialis™ Supermodel

Transforms training, validation, and compound-specific datasets into a common data space of cancer biology.

Genialis biomarker icon

3. Genialis™ krasID

Genialis krasID comprises the top 20 biological signatures describing KRAS biology.

patient stratification icon

4. Classifier for your drug

Once tuned, the resulting compound-specific krasID classifier defines clinically relevant subtypes.

Genialis krasID is the first and only biomarker that can accurately stratify KRAS patients by clinical response

Its predictions are consistent with real world and clinical findings.

  • Real World Data
    Patients stratified as krasID-High vs. krasID-Low demonstrate dramatically different time on treatment

  • Clinical Trial
    Cohort characteristics and response results align closely with CodeBreaK100/200 clinical trial observations, demonstrating accuracy in forecasting outcomes in clinical trial settings.

  • Time on Treatment
    krasID-High patients stayed on sotorasib nearly 50% longer than G12C-selected patients and ~2.0x longer than krasID-Low patients

KM plot of predicted benefit to sotorasib in a NSCLC RWE cohort

Genialis™ krasID outperforms current Standard of Care Biomarkers, which are limited to mutational status

Historical Approach

  • Limited to presence or absence of DNA mutation

  • Perhaps necessary, but utterly insufficient to predict efficacy (mutation selected ORR ~ 30-40%)

  • Cannot inform time on treatment or combination strategies

Genialis™ krasID Advantage

  • Integrates signal from KRAS biology with surrounding tumor milieu using RNA-seq & ML

  • Predicts response with >94% accuracy in preclinical models and >80% accuracy in real world patients

  • Stratifies patients based on time on treatment/survival

  • Reads out actionable changes to other therapeutically relevant biologies

The current KRASi development landscape is crowded; Next-generation biomarkers will provide differentiation

Two drugs currently on market

FDA approved KRAS G12C Inhibitors

Competition to get to market

>50 companies competing across ~7 different solid tumor indications 2

Competition to get to market, >50 companies competing across ~7 different solid tumor indications

1 Tian H, Yang Z, He J. Adagrasib: A landmark in the KRASG12C-mutated NSCLC. MedComm (2020). 2022 Nov 25;3(4):e190. doi: 10.1002/mco2.190. PMID: 36448054; PMCID: PMC9697582.
2 Biocentury Inc. “KRAS Pipeline” (2024)

More than 50 companies are competing to bring KRAS drugs to market, with the ‘best-in-class’ distinction yet to be claimed.

Gain the edge for clinical trial success and market share by stratifying your patient population with 80% predictability.

We welcome you to explore & evaluate Genialis™ krasID.
Schedule a free consultation with our experts to begin!